Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is particularly modest. We hope to catch up on our fast-growing reading list, take a few naps, and hang with a short person or two. We may also putter around the castle. And what about you? Spring is edging closer, so perhaps this is a good time to plan a getaway or get a head start on cleaning out the closets. You could also enjoy a moving picture or make time for someone special. Life is short, you know. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Sanofi (SNY) suffered a major setback in its bid to market its controversial dengue vaccine in the U.S., as a Food and Drug Administration advisory committee recommended against approval for adults, STAT writes. The drug maker had asked the agency to approve Dengvaxia for people aged 9 to 45. But the advisory panel recommended the agency license the vaccine only for people ages 9 to less than 17. Dengvaxia is the first dengue vaccine to make it to market anywhere in the world, but has accompanied by enormous problems and scandal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!